Global Health Investment Corporation

BARDA

"Today, we are announcing an innovative, cost-effective approach that puts us on a better path to take on the next public health crisis." – U.S. HHS Secretary Xavier Becerra

GHIC is partnering with BARDA to use venture capital practices to accelerate the development and introduction of technologies and medical products to respond to or prevent global public health emergencies and other health security threats.

GHIC manages this BARDA-funded partnership, leveraging our global health investment and commercialization experience while benefiting from BARDA’s scientific and technical input. GHIC will identify companies with the most promising technologies to help strengthen global health security. To amplify the impact of BARDA's funding, GHIC will mobilize additional capital from other investors. GHIC will also join BARDA in fostering and strengthening the ecosystem of innovation for technologies relevant to pandemic preparedness.

Through this partnership, BARDA intends to provide GHIC with a minimum of $50 million in funding over five years with potential for up to $500 million during the course of the 10-year agreement. GHIC will raise matching capital from other investors across the public, philanthropic and private sectors, and launch a global health security investment fund. As the fund’s portfolio companies generate investment returns, proceeds from BARDA’s investment capital will be recycled by GHIC into additional investments.  These investments will also be designed to advance the goals of the partnership, further amplifying the mission impact of BARDA’s initial funding.

Learn more about BARDA and BARDA Ventures here.

 

Portfolio Investments

Biolinq . Opens in new tab.

Intervention: Device

Targets: Diabetes, pre-diabetes, other diseases

Impact Objectives: Improve management of various clinical conditions and detect exposure to multiple public health agents